Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (smallpox)

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6246-6253

  Mucker, Eric M ^a   Goff, Arthur J ^a   Shamblin, Joshua D ^a   Grosenbach, Douglas W ^b   Damon, Inger K ^c   Mehal, Jason M ^d   Holman, Robert C ^d   Carroll, Darin ^c   Gallardo, Nadia ^c   Olson, Victoria A ^c   Clemmons, Cody J ^c   Hudson, Paul ^c   Hruby, Dennis E ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b SIGA Technologies Incorporated   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TECOVIRIMAT; VIRUS DNA;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MACACA FASCICULARIS; MALE; NONHUMAN; OROPHARYNX; PRIMATE; PRIORITY JOURNAL; SMALLPOX; SMALLPOX VIRUS; SURVIVAL RATE; VIRUS SHEDDING;

ANIMALS; ANTIVIRAL AGENTS; BENZAMIDES; ISOINDOLES; MACACA; MALE; POXVIRIDAE INFECTIONS; RANDOM ALLOCATION; TREATMENT OUTCOME; VARIOLA VIRUS;

EID: 84887453859     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00977-13     Document Type: Article

References (34)

1. Barquet N, Domingo P. 1997. Smallpox: the triumph over the most terrible of the ministers of death. Ann. Intern. Med. 127:635-642.
2. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. 1988. Smallpox and its eradication. WHO, Geneva, Switzerland.
3. Breman JG, Henderson DA. 2002. Diagnosis and management of smallpox. N. Engl. J. Med. 346:1300-1308.
4. Phadke AM, Samant NR, Dewal SD. 1973. Smallpox as an etiologic factor in male infertility. Fertil. Steril. 24:802-804.
5. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37:251-271.
6. Henderson DA. 1999. The looming threat of bioterrorism. Science 283: 1279-1282.
7. Smith GL, Vanderplasschen A, Law M. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
8. Kretzschmar M, van den Hof S, Wallinga J, van Wijngaarden J. 2004. Ring vaccination and smallpox control. Emerg. Infect. Dis. 10:832-841.
9. Kaplan EH. 2004. Preventing second-generation infections in a smallpox bioterror attack. Epidemiology 15:264-270.
10. Legrand J, Viboud C, Boelle PY, Valleron AJ, Flahault A. 2004. Modelling responses to a smallpox epidemic taking into account uncertainty. Epidemiol. Infect. 132:19-25.
11. Kaplan EH, Craft DL, Wein LM. 2002. Emergency response to a smallpox attack: the case for mass vaccination. Proc. Natl. Acad. Sci. U. S. A. 99:10935-10940.
12. Meltzer MI, Damon I, LeDuc JW, Millar JD. 2001. Modeling potential responses to smallpox as a bioterrorist weapon. Emerg. Infect. Dis. 7:959-969.
13. Fenner F, Henderson D, Arita I, Jezek Z, Ladnyi I. 1988. The pathogenesis, pathology, and immunology of smallpox and vaccinia, p 122-167. In Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
14. Yang G, Pevear DC, Davies MH, Collett MS, Bailey T, Rippen S, Barone L, Burns C, Rhodes G, Tohan S, Huggins JW, Baker RO, Buller RL, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K, Hruby D, Jordan R. 2005. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79:13139-13149.
15. Chen Y, Honeychurch KM, Yang G, Byrd CM, Harver C, Hruby DE, Jordan R. 2009. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 6:44.
16. Blasco R, Moss B. 1991. Extracellular vaccinia virus formation and cellto-cell virus transmission are prevented by deletion of the gene encoding the 37, 000-dalton outer envelope protein. J. Virol. 65:5910-5920.
17. Payne LG. 1980. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 50:89-100.
18. Gurt I, Abdalrhman I, Katz E. 2005. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R. Antiviral Res. 69:158-164.
19. McIntosh AA, Smith GL. 1996. Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J. Virol. 70:272-281.
20. Wolffe EJ, Isaacs SN, Moss B. 1993. Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J. Virol. 67:4732-4741.
21. Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, Huggins JW. 2004. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U. S. A. 101:15196-15200.
22. Wahl-Jensen V, Cann JA, Rubins KH, Huggins JW, Fisher RW, Johnson AJ, de Kok-Mercado F, Larsen T, Raymond JL, Hensley LE, Jahrling PB. 2011. Progression of pathogenic events in cynomolgus macaques infected with variola virus. PLoS One 6:e24832. doi:10.1371/journal.pone.0024832.
23. Huggins J, Goff A, Hensley L, Mucker E, Shamblin J, Wlazlowski C, Johnson W, Chapman J, Larsen T, Twenhafel N, Karem K, Damon IK, Byrd CM, Bolken TC, Jordan R, Hruby D. 2009. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 53:2620-2625.
24. Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK. 2012. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J. Infect. Dis. 206:1372-1385.
25. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL, Gerber SI, Garcia-Houchins S, Lederman E, Hruby D, Collins L, Scott D, Thompson K, Barson JV, Regnery R, Hughes C, Daum RS, Li Y, Zhao H, Smith S, Braden Z, Karem K, Olson V, Davidson W, Trindade G, Bolken T, Jordan R, Tien D, Marcinak J. 2008. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46: 1555-1561.
26. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, Marbury T, Lichtenstein I, Pickens M, Corrado M, Landis P, Clarke JM, Frimm AM, Hruby DE. 2012. Pharmacokinetic comparison of a single oral dose of polymorph form I versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers. Antimicrob. Agents Chemother. 56:3582-3586.
27. Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE. 2012. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob. Agents Chemother. 56:4900-4905.
28. Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE. 2010. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 54:2560-2566.
29. Berhanu A, King DS, Mosier S, Jordan R, Jones KF, Hruby DE, Grosenbach DW. 2009. ST-246(R) inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob. Agents Chemother. 53:4999-5009.
30. Grosenbach DW, Berhanu A, King DS, Mosier S, Jones KF, Jordan RA, Bolken TC, Hruby DE. 2010. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc. Natl. Acad. Sci. U. S. A. 107: 838-843.
31. Quenelle DC, Buller RM, Parker S, Keith KA, Hruby DE, Jordan R, Kern ER. 2007. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 51:689-695.
32. Sbrana E, Jordan R, Hruby DE, Mateo RI, Xiao SY, Siirin M, Newman PC, Da Rosa AP, Tesh RB. 2007. Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am. J. Trop. Med. Hyg. 76:768-773.
33. Nalca A, Hatkin JM, Garza NL, Nichols DK, Norris SW, Hruby DE, Jordan R. 2008. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res. 79:121-127.
34. Jordan R, Goff A, Frimm A, Corrado ML, Hensley LE, Byrd CM, Mucker E, Shamblin J, Bolken TC, Wlazlowski C, Johnson W, Chapman J, Twenhafel N, Tyavanagimatt S, Amantana A, Chinsangaram J, Hruby DE, Huggins J. 2009. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 53:1817-1822.